Citius Oncology, INC. (CTOR) — 10-K Filings
All 10-K filings from Citius Oncology, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Citius Oncology Launches LYMPHIR Amidst Going Concern Doubts
— Dec 23, 2025 Risk: high
Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on targeted oncology therapies, with its lead product LYMPHIR™ (denileukin diftitox) approve -
CITIUS ONCOLOGY, INC. Files 2024 Annual Report
— Dec 27, 2024 Risk: low
CITIUS ONCOLOGY, INC. filed its annual report for the fiscal year ended September 30, 2024. The company, formerly known as TenX Keane Acquisition until March 15 -
TenX Keane Acquisition Files 2023 Annual Report on Form 10-K
— Apr 16, 2024 Risk: low
TenX Keane Acquisition (CTOR) filed a Annual Report (10-K) with the SEC on April 16, 2024. TenX Keane Acquisition filed its annual report for the fiscal year en
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX